×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
NVS – novartis ag (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
NVS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/17
06:42 am
nvs
Novartis AG (NYSE: NVS) was upgraded by analysts at BNP Paribas to a "strong-buy" rating.
Low
Report
Novartis AG (NYSE: NVS) was upgraded by analysts at BNP Paribas to a "strong-buy" rating.
4/16
04:28 am
nvs
Thyroid Eye Disease Treatment Market Forecast to Reach $11.81 Billion by 2031 | Emerging Economies Expand Access to Thyroid Eye Disease Diagnoses and Therapies [Yahoo! Finance]
Low
Report
Thyroid Eye Disease Treatment Market Forecast to Reach $11.81 Billion by 2031 | Emerging Economies Expand Access to Thyroid Eye Disease Diagnoses and Therapies [Yahoo! Finance]
4/14
08:35 am
nvs
Liver Fluke Treatment Market Growth Drivers, Industry Trends and Forecasts 2025-2034 | Global Liver Fluke Treatment Market Grows at 4.8% CAGR Amid Rising Anthelmintic Drug Demand [Yahoo! Finance]
Low
Report
Liver Fluke Treatment Market Growth Drivers, Industry Trends and Forecasts 2025-2034 | Global Liver Fluke Treatment Market Grows at 4.8% CAGR Amid Rising Anthelmintic Drug Demand [Yahoo! Finance]
4/14
08:19 am
nvs
Saisei Ventures Launches Executive Fellows Program Aiming to Enhance Japan's Biotech Leadership Pipeline [Yahoo! Finance]
Low
Report
Saisei Ventures Launches Executive Fellows Program Aiming to Enhance Japan's Biotech Leadership Pipeline [Yahoo! Finance]
4/14
07:19 am
nvs
Bio-Thera Solutions Presents Clinical Data for multiple products at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]
Low
Report
Bio-Thera Solutions Presents Clinical Data for multiple products at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]
4/14
05:08 am
nvs
Novartis (NVS) Surges 4.0%: Is This an Indication of Further Gains? [Yahoo! Finance]
Low
Report
Novartis (NVS) Surges 4.0%: Is This an Indication of Further Gains? [Yahoo! Finance]
4/11
03:22 pm
nvs
NVS Plans to Invest $23B in US Manufacturing Sites Amid Tariff Threat [Yahoo! Finance]
Low
Report
NVS Plans to Invest $23B in US Manufacturing Sites Amid Tariff Threat [Yahoo! Finance]
4/10
02:29 pm
nvs
Novartis plans to invest $23 billion in US plants as Trump renews drug tariff threats [CNBC]
Low
Report
Novartis plans to invest $23 billion in US plants as Trump renews drug tariff threats [CNBC]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/3
06:01 am
nvs
Form 6-K NOVARTIS AG For: Apr 03
Low
Report
Form 6-K NOVARTIS AG For: Apr 03
3/28
02:01 pm
nvs
Form 6-K NOVARTIS AG For: Mar 28
Low
Report
Form 6-K NOVARTIS AG For: Mar 28
1/31
07:16 am
nvs
Form 6-K NOVARTIS AG For: Dec 31
Low
Report
Form 6-K NOVARTIS AG For: Dec 31
1/31
07:14 am
nvs
Form 6-K NOVARTIS AG For: Dec 31
Low
Report
Form 6-K NOVARTIS AG For: Dec 31
1/31
07:08 am
nvs
Form 20-F NOVARTIS AG For: Dec 31
Low
Report
Form 20-F NOVARTIS AG For: Dec 31
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/4
BRIEF-Novartis has stock to cover production, distribution for now, monitoring India API changes [Reuters]
4.8%
7/17 The Multibillion-Dollar Race for Gene Therapy Manufacturing Is On [The Motley Fool] 4.5%
5/23 Sosei Heptares Notes That a Valid Marketing Authorization Application For QVM149, a Potential New Inhaled Combination Therapy For Asthma, Has Been Filed With the European Medicines Agency 3.6%
8/11 5 Reasons Novartis Shareholders Aren't Shaken [The Motley Fool] 3.4%
8/7 Glancy Prongay & Murray LLP Announces Investigation on Behalf of Novartis AG Investors (NVS) 2.7%
4/4 Novartis AG (NYSE: NVS) had its "buy" rating re-affirmed by analysts at Goldman Sachs Group Inc. They now have a $116.00 price target on the stock. 2.7%
4/13 Novartis: Recent Selloff Has Presented A Buying Opportunity [Seeking Alpha] 2.4%
3/24 BRIEF-Novartis says Zolgensma helped SMA patients up to 5 years after dosing [Reuters] 2.2%
4/2 New York City hospital worker who caught coronavirus returns to treat patients [FOX News] 2.2%
3/10 INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm 1.9%
7/17 The Multibillion-Dollar Race for Gene Therapy Manufacturing Is On [The Motley Fool] 4.5%
5/23 Sosei Heptares Notes That a Valid Marketing Authorization Application For QVM149, a Potential New Inhaled Combination Therapy For Asthma, Has Been Filed With the European Medicines Agency 3.6%
8/11 5 Reasons Novartis Shareholders Aren't Shaken [The Motley Fool] 3.4%
8/7 Glancy Prongay & Murray LLP Announces Investigation on Behalf of Novartis AG Investors (NVS) 2.7%
4/4 Novartis AG (NYSE: NVS) had its "buy" rating re-affirmed by analysts at Goldman Sachs Group Inc. They now have a $116.00 price target on the stock. 2.7%
4/13 Novartis: Recent Selloff Has Presented A Buying Opportunity [Seeking Alpha] 2.4%
3/24 BRIEF-Novartis says Zolgensma helped SMA patients up to 5 years after dosing [Reuters] 2.2%
4/2 New York City hospital worker who caught coronavirus returns to treat patients [FOX News] 2.2%
3/10 INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm 1.9%
TOP News Decliners
2/24
BRIEF-Novartis Announces FDA And EMA Filing Acceptance Of Ofatumumab [Reuters]
-6.9%
4/28 Novartis sales, profits rise in first quarter on COVID-19 buying rush [Reuters (UK)] -3.2%
2/25 Novartis AG (NYSE: NVS) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating. -3.0%
9/13 BRIEF-Novartis Says Neuronal And Glial Filaments Have Potential To Support Management Of MS Patient [Reuters] -2.8%
4/6 Special Report: Doctors embrace drug touted by Trump for COVID-19, without hard evidence it works [Reuters] -2.7%
3/3 BRIEF-Novartis Receives Health Canada Approval For Mayzent [Reuters] -2.7%
3/20 UPDATE 2-Novartis to donate malaria drug in fight against coronavirus [Reuters] -2.4%
7/11 BRIEF-Novartis, Amgen And Banner Alzheimer's Institute Discontinue Clinical Program With Bace Inhibitor CNP520 [Reuters] -2.3%
3/9 ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against Novartis AG – NVS -2.2%
3/20 Novartis to donate malaria drug in fight against coronavirus [Reuters] -2.2%
4/28 Novartis sales, profits rise in first quarter on COVID-19 buying rush [Reuters (UK)] -3.2%
2/25 Novartis AG (NYSE: NVS) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating. -3.0%
9/13 BRIEF-Novartis Says Neuronal And Glial Filaments Have Potential To Support Management Of MS Patient [Reuters] -2.8%
4/6 Special Report: Doctors embrace drug touted by Trump for COVID-19, without hard evidence it works [Reuters] -2.7%
3/3 BRIEF-Novartis Receives Health Canada Approval For Mayzent [Reuters] -2.7%
3/20 UPDATE 2-Novartis to donate malaria drug in fight against coronavirus [Reuters] -2.4%
7/11 BRIEF-Novartis, Amgen And Banner Alzheimer's Institute Discontinue Clinical Program With Bace Inhibitor CNP520 [Reuters] -2.3%
3/9 ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against Novartis AG – NVS -2.2%
3/20 Novartis to donate malaria drug in fight against coronavirus [Reuters] -2.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: